The landscape of clinical research in the United Kingdom is undergoing a significant transformation. Driven by the Medicines and Healthcare products Regulatory Agency (MHRA), a new initiative—the Women’s Health Programme—has been launched to address a systemic, decades-long failure in medical science: the chronic underrepresentation of women, particularly those who are pregnant or breastfeeding, in the development of pharmaceuticals and medical devices.
The announcement, made during the prestigious Drug Information Association (DIA)-MHRA Global Summit at London Life Sciences Week, signals a definitive pivot in how the UK intends to approach gender-specific data. By fostering a regulatory environment that demands inclusivity, the MHRA aims to ensure that the medicines and technologies of tomorrow are backed by robust, gender-disaggregated evidence.
The Data Reality: A Stark Disparity
The necessity for this programme is underpinned by sobering statistics. An exhaustive analysis of 4,616 clinical trial applications submitted to the MHRA between 2019 and 2023 revealed a profound oversight. Despite women comprising 51% of the UK population, they remain a "clinical minority" in the laboratory.
The data is particularly alarming regarding maternal health: pregnant women were represented in a mere 1.1% of clinical trials, while breastfeeding women appeared in only 0.6%. This is not merely a statistical anomaly; it is a fundamental flaw in the design of clinical research that leaves millions of patients to navigate treatments without the assurance of safety or efficacy data tailored to their specific physiological states.
This issue is not confined to the UK’s borders. Globally, pregnant women account for only 4% of participants in clinical trials. As the scientific community increasingly acknowledges, pregnancy and the postpartum period involve complex physiological changes—from altered metabolism to changes in fluid volume—that can dramatically affect how a patient processes a pharmaceutical or interacts with a medical device. Without inclusive data, the medical community is often forced to rely on "best guesses" or exclusion, neither of which is acceptable in modern, evidence-based medicine.
Chronology of a Regulatory Shift
The launch of the Women’s Health Programme is the culmination of years of advocacy and evolving regulatory priorities.
- 2019–2023: The period of data analysis during which the MHRA identified the 1.1% and 0.6% representation figures, providing the empirical foundation for current policy reform.
- Early 2026: Leading voices in the industry, including Sheila Diamond of Medidata, began a public campaign calling for shared responsibility among stakeholders to dismantle the barriers preventing the inclusion of pregnant and breastfeeding women in research.
- November 2026: During the DIA-MHRA Global Summit in London, the MHRA officially unveiled the Women’s Health Programme, embedding it into the broader national agenda of the UK’s Women’s Health Strategy.
- The Future: The programme is set to influence upcoming trial design protocols, with an expected increase in scrutiny for new applications that fail to justify the exclusion of female populations.
Official Perspectives: Shifting the Paradigm
The political and industry response has been one of decisive support, reflecting a growing consensus that the status quo is untenable.
Baroness Gillian Merron, the UK’s Women’s Health Minister, was unequivocal in her assessment of the current landscape. "For too long, women’s health has been overlooked," she stated. "Women make up more than half of our population, yet they have been underrepresented in the research that shapes the medicines and devices they rely on. That is not good enough, and we are determined to change it."
For the government, this programme is not just about clinical data; it is about equity. By integrating this initiative with the broader Women’s Health Strategy, the UK aims to build a health system that is fundamentally designed to listen to women.
From the private sector, the reaction has been equally positive. Michelle Riddalls OBE, CEO of the Consumer Healthcare Association (PAGB), highlighted the potential for the programme to empower patients. "Better evidence can help women make more informed choices," Riddalls noted. She pointed out that improved data could even facilitate the "reclassification of medicines," moving certain drugs from prescription-only to over-the-counter status, thereby supporting women in managing their health through self-care.
The FemTech Conundrum: Innovation vs. Regulation
A critical component of the MHRA’s new focus is the burgeoning FemTech sector. In the UK alone, this industry boasts an annual turnover of nearly £300 million ($396 million). These technologies, which range from diagnostic apps to wearable devices for reproductive health and healthy ageing, represent a massive opportunity for the UK economy and public health.

However, the rapid pace of innovation has left regulators playing catch-up. David Hill, a partner at the law firm Browne Jacobson, argues that while the Women’s Health Programme is a vital step, the regulatory framework must evolve to address the unique nature of software-based medical tools.
"FemTech covers a wide range of software, diagnostics, and apps," Hill explained. "Yet regulation of software-based health tools has not kept up with state-of-the-art technology that is advanced enough to actively intervene in a user’s health in a manner more akin to physical medical devices."
Hill identified a specific regulatory loophole: the "wellness" classification. Many digital health applications use the "tracking" label to categorize themselves as lifestyle tools rather than medical devices. This allows developers to sidestep the rigorous clinical scrutiny required for true medical interventions. The MHRA’s programme is expected to cast a wider, more critical eye on these technologies to ensure that "wellness" apps that provide health-altering advice are held to the same safety and evidence standards as traditional pharmaceuticals.
Implications for the Future of Healthcare
The implications of this programme are far-reaching, affecting pharmaceutical companies, device manufacturers, and, most importantly, the patients themselves.
1. Enhanced Trial Design
The most immediate impact will be on the pharmaceutical and MedTech industries. Companies applying for trial authorization will likely face increased scrutiny regarding their inclusion criteria. The "default" exclusion of women of reproductive age will no longer be an accepted standard without rigorous justification. This will force a shift toward more sophisticated trial designs that account for hormonal fluctuations and pregnancy-related physiological changes.
2. A "Safety-First" Approach
By increasing the volume of data on how women respond to treatments, the MHRA aims to reduce the incidence of adverse drug reactions (ADRs) that occur when drugs are tested primarily on male subjects. This is a matter of patient safety; it ensures that the "one-size-fits-all" approach to medicine is replaced by one that accounts for biological diversity.
3. Boosting the FemTech Ecosystem
By clarifying the regulatory pathway for digital health tools, the MHRA can provide the necessary legal certainty for investors and developers. If the UK can establish a robust, world-leading regulatory framework for FemTech, it could solidify its position as the global hub for women’s health innovation. This would allow legitimate innovators to bring products to market faster, knowing they are backed by a seal of regulatory approval that patients and doctors can trust.
4. Patient Empowerment and Self-Care
As Michelle Riddalls highlighted, the end goal is to provide women with the information they need to manage their own health. When products are tested correctly, they can be safely reclassified, granting women greater autonomy. Whether it is through better access to reproductive health diagnostics or more precise treatment for long-term conditions, the programme promises a more responsive, personalized healthcare system.
Conclusion: A Turning Point for Medicine
The launch of the Women’s Health Programme by the MHRA is more than a administrative policy change; it is a recognition of a systemic failure in the scientific method. For decades, the omission of women from clinical trials has created a "knowledge gap" that has compromised the quality of care for millions.
As the UK moves forward with this initiative, the eyes of the global scientific community will be on London. If the MHRA succeeds in mandating inclusivity in clinical trials and bringing the rapidly evolving FemTech sector under a clearer, more rigorous regulatory umbrella, it will set a new global standard. The ultimate success of this programme will be measured not in the number of applications processed or the amount of turnover in the FemTech sector, but in the improved health outcomes and increased trust of women across the UK and beyond. The era of overlooking half the population is coming to an end; the era of inclusive, evidence-based, and equitable medicine has begun.
